You are here
Family Bank: Cordlife Group Limited
Cordlife Group Limited ("Cordlife", together with its subsidiaries, the "Group") is a consumer healthcare company catering to the mother and child segment. Established in May 2001 and successfully listed on the Mainboard of Singapore Exchange Trading Limited ("SGX-ST") in 2012, the Group is one of the pioneers in the cord blood banking industry in Asia. Cordlife has the largest market share among private cord blood banks in Singapore, the Philippines and Indonesia. It is among the Top 3 market leaders in Hong Kong and India. In February 2017, Cordlife increased its shareholding in Stemlife, the largest cord blood bank in Malaysia, to 99.03%, making it the latest subsidiary of the Group. Cordlife is also the first Singapore private cord blood bank in Myanmar and Vietnam.
Labs and Locations
Cordlife Group Limited
1 Yishun Industrial Street 1 #06-01/09,
A'Posh Bizhub Singapore 768160
Cordlife is amongst the leading players for private cord blood banking services in all the markets it operates in, namely Singapore, Hong Kong, Malaysia, India, Indonesia and the Philippines. Inhabiting a distinctive niche in the healthcare industry, the Group is one of the foremost private cord blood banks to have gained a solid foothold in Asia. In the last 16 years, Cordlife has dedicated its undertakings to achieve market leadership in the industry. Having built a distinguished brand name, the Group continues to strive for excellence by means of support from its experienced management team, dynamic key executives along with its quality product and service offerings. Cordlife believes the Group has in place a strong foundation for future expansion.
The Group's processing and storage facilities in Hong Kong, India and Singapore are accredited by AABB, the world's gold standard in cord blood banking and its facilities in Indonesia and the Philippines are also ISO-certified. Cordlife Singapore achieved accreditation by FACT-Netcord, making it one of only six cord blood banks in the world to achieve accreditations from both AABB and FACT-Netcord simultaneously. The Group’s majority owned Hong Kong and India subsidiaries, Hong Kong Screening Centre Limited (“HKSC”) and Cordlife Sciences (India) Pvt. Ltd. (“Cordlife India”), have also received accreditation from the College of American Pathologists (“CAP”), which is awarded to facilities that meet or exceed the highest standards in laboratory services. In July 2017, Cordlife Philippines became the first cord blood bank in the country to be accredited by AABB.
The kit contains a closed system blood bag (brand JMS) that is pre-loaded with the anti-coagulant CPDA-1. The kit also provides the disinfectant Povidone-iodine.
The collection kit is constructed with thermal insulation and validated to maintain room temperature for up to 48 hours during transportation back to the laboratory.
Cordlife provides dedicated staff to pick up the cord blood sample from Singapore hospitals upon notification.
Stem cells are separated from the cord blood using the fully automated and closed Sepax system from Biosafe. The final component is the buffy coat layer of the blood, which holds both white cells and stem cells.
Parents are provided with a report describing test results for the buffy coat holding white cells and stem cells including total nucleated cells (TNC), post processing sterility, viable CD34+ counts, as well as maternal blood infectious disease results.
Final cord blood storage is in 25 ml blood (cryo) bag encased in an overwrap. Blood samples are kept in a quarantine freezer, then moved to long term freezer after they pass testing. Stem cells are stored in the vapour phase of cryogenic nitrogen.
Licensing & Accreditation
- Certified by Singapore Ministry of Health
- Accredited by AABB
- Accredited by FACT
- Cordlife Singapore is the first bank in Southeast Asia and one of the six cord blood banks in the world, to achieve dual AABB & FACT accreditation
Cordlife Group Limited has a successful transplant track record of 36 cord blood units.
Cordlife clients will be covered by a program known as the Cordlife Care360 – a holistic program aimed to safeguard our client and their family.
1) Cordlife provides the coverage of possible pregnancy and childbirth complications*.
2) Cordlife will cover future storage payments if death or total permanent disability* occurs to either biological parent of Child during the contractual storage period.
3) Cordlife assures clients a cord blood unit of suitable match or US$25,000 to defray medical costs if the cord blood loses its viability at point of transplant*.
4) Cordlife will cover the cost for additional tests required in the event of a transplant* - matching (HLA resolution test) and viability (CFU assay).
5) Cordlife has taken additional insurance coverage, to safeguard client and their family from financial loss resulting from direct malpractice*.
* Terms and Conditions apply
For more information, please submit a price plan enquiry
Cordlife has an exclusive license on patented technology to harvest and store two types of stem cells from the lining of the umbilical cord. This cord lining contains both Epithelial Stem Cells (EpSC) and Mesenchymal Stem Cells (MSC).